Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28482038 | 0.85 | VNN1 (0.42) | VNN1 | |
| SCHEMBL21460176 | 0.85 | VNN1 (0.42) | VNN1 | |
| SCHEMBL3447624 | 0.84 | GABRR1 (0.34) | VNN1 | |
| SCHEMBL21196146 | 0.75 | VNN1 (0.32) | VNN1 | |
| SCHEMBL20973530 | 0.75 | — | — | |
| SCHEMBL1700286 | 0.75 | — | — | |
| SCHEMBL23930873 | 0.73 | SLC6A12 (0.34) | — | |
| SCHEMBL12492404 | 0.73 | SLC6A12 (0.34) | — | |
| SCHEMBL19024199 | 0.73 | — | — | |
| SCHEMBL23528022 | 0.73 | SMYD3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414247-B1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3414247-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137334-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | VNN1 2560/4885 |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | VNN1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.